With the health and safety of members, volunteers, and attendees in mind, SNMMI made the decision to reschedule the SNMMI Therapeutics Conference, originally scheduled for November 11-13, 2021. The SNMMI Therapeutics Conference will now take place March 10-12, 2022, in New Orleans, LA. Read the full date change announcement.
SNMMI members can save 50% when they register to attend SNMMI's Online Nuclear Medicine Review Course and in-training resident members can register for free. This two-day course is the perfect resource to help you prepare for your board exam or use as a great general refresher to enhance your practice! Register.
ACNM Annual Meeting abstract submission window opens in September. Sign up to be contacted when more information becomes available for 2022 SNMMI Mid-Winter and ACNM Annual Meeting.
Welcome to our Healthcare Provider portal. Everything you need to understand the advantages and applications of nuclear medicine and molecular imaging in your practice. Find out more about ordering the right test for the right patient at the right time.
Appropriate Use Criteria (AUC) are statements that contain indications describing when, and how often, an intervention should be performed under the auspices of scientific evidence, clinical judgment, and patient values while avoiding unnecessary provisions of services. SNMMI follows a balanced multidisciplinary approach to guidance development by including various stakeholders in the development process. To view the development process, please click the following link: SNMMI AUC Development Process.
SNMMI has created guidelines to identify those elements of the procedure that are most important in obtaining a high-quality examination, Appropriate Use Criteria (AUC), and is working towards optimizing dose.
Appropriate Use Criteria
NCCN's Guidelines Tabular Summary
NCCN Practice Guidelines Narrative Summary
The SNMMI PET Center of Excellence has created a go-to resource with in-depth ordering information and printable materials related to PET and PET/CT, including:
SNMMI is dedicated to providing the community with access to the most knowledgeable and experienced speakers in the field of nuclear medicine and molecular imaging. As part of the new Outreach Program, SNMMI is working to enhance relationships with relevant societies and patient organizations. We have created a pool of speakers who can speak at your next meeting. Please complete the form below to request a speaker.
Outreach Speaker Request Form
PSMA PET mapping of cancer recurrence in the prostate bed shows that current radiotherapy contouring guidelines—which determine the target areas for treatment—miss a significant number of lesions and may unnecessarily irradiate healthy tissues, according to a new study published ahead of print in JNM. Researchers are calling for redefinition of the guidelines to improve patient outcomes.
A novel, palm-sized imaging modality that can visualize the distribution of medical radiopharmaceuticals with very fine resolution has been developed and successfully tested, according to research published in March JNM. Known as the lensless radiomicroscope, the instrument offers the same level of imaging performance as its closest imaging equivalent but comes with significantly larger field of view and costs less than $100.
A new radiotracer, Ga-68 FAP-2286, has been found to be more effective than the most commonly used nuclear medicine cancer imaging radiotracer, F-18 FDG, according to a study published in JNM. Ga-68 FAP-2286 detected 100 percent of primary tumors across multiple cancer types as compared to F-18 FDG, which identified only 80 percent. Ga-68 FAP-2286 was also more effective in detecting lymph node metastases and distant metastases.
SNMMI, along with more than 80 stakeholder organizations, supports and applauds the introduction of H.R. 1199, the Facilitating Innovative Nuclear Diagnostic (FIND) Act of 2023. The legislation will ensure patient access to innovative and effective diagnostic imaging.
SNMMI monitors multiple federal legislative issues and provides resources including issue summaries, letters to Congress, and analysis. Most of this information is in the government relations news section of this web site.
The SNMMI Qualified Systems Personnel Training Program (QSPTP) has been developed to define the competencies of a Qualified Person in the release of manufactured radiopharmaceuticals. It is intended to provide experts in the field of radiopharmaceutical science guidance in program development